ImmunityBio (IBRX) director exercises options and sells 25,000 shares

Rhea-AI Filing Summary

ImmunityBio, Inc. director Christobel Selecky reported an option exercise and share sale. On February 23, 2026, she exercised a stock option for 25,000 shares, acquiring an equal number of ImmunityBio common shares at a price of $2.98 per share through the derivative conversion. A related option line shows 25,000 stock option rights exercised, with 67,937 options remaining directly owned after the transaction. On the same date, she then sold 25,000 common shares at $10.00 per share, leaving 0 shares from that lot directly owned after the sale. The sale was carried out under a Rule 10b5-1 trading plan adopted on June 12, 2025, and all shares underlying the option had fully vested on June 12, 2023.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Selecky Christobel

(Last) (First) (Middle)

C/O IMMUNITYBIO, INC.

3530 JOHN HOPKINS COURT

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ImmunityBio, Inc. [ IBRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/23/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/23/2026		M		25,000	A	$2.98	25,000	D
Common Stock	02/23/2026		S(1)		25,000	D	$10	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$2.98	02/23/2026		M			25,000	(2)	06/14/2032	Common Stock	25,000	$0	67,937	D

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2025.

2. One hundred percent (100%) of the shares subject to the award vested on June 12, 2023, the date immediately preceding the 2023 annual meeting of stockholders.

Remarks:

	/s/ Philip LoScalzo, as Attorney-in-Fact	02/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did ImmunityBio (IBRX) director Christobel Selecky report?

Christobel Selecky reported exercising options and selling shares. On February 23, 2026, she exercised options into 25,000 ImmunityBio common shares and sold 25,000 common shares in the open market, all reported as direct ownership transactions.

How many ImmunityBio (IBRX) shares did Christobel Selecky sell and at what price?

She sold 25,000 ImmunityBio common shares at $10.00 per share. The transaction, dated February 23, 2026, was reported as an open-market or private sale, leaving zero shares from that sold lot directly owned afterward.

What stock options did Christobel Selecky exercise in this ImmunityBio (IBRX) Form 4?

She exercised stock options for 25,000 shares of ImmunityBio. The derivative transaction converted 25,000 option rights into 25,000 common shares, and 67,937 stock options remained directly owned following the exercise.

What price did Christobel Selecky pay to acquire ImmunityBio (IBRX) shares from the option exercise?

The acquired common shares are reported at $2.98 per share. The Form 4 shows 25,000 ImmunityBio common shares associated with a derivative exercise/conversion at a reported transaction price of $2.98 per share.

Was Christobel Selecky’s ImmunityBio (IBRX) share sale under a Rule 10b5-1 plan?

Yes, the sale occurred under a Rule 10b5-1 trading plan. A footnote states the sales were effected pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2025.

When did the ImmunityBio (IBRX) option award to Christobel Selecky fully vest?

The option award fully vested on June 12, 2023. A footnote explains that 100% of the shares subject to the award vested on that date, immediately before the 2023 annual meeting of stockholders.